Hims & Hers Health (NYSE:HIMS) Stock: Insider Soleil Boughton Sells 3,462 Shares

Hims & Hers Health, Inc. (NYSE:HIMS) insider Soleil Boughton sold 3,462 shares of Hims & Hers Health stock in a transaction that occurred on Wednesday, October 28th. The shares were sold at an average price of $27.60, for a total value of $95,551.20. Following the sale, the insider directly owned 293,886 shares in the company, valued at $8,111,253.60. This trade represents a 1.16% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Soleil Boughton also recently made the following trade(s):

• On Wednesday, October 14th, Soleil Boughton sold 3,461 shares of Hims & Hers Health stock. The shares were sold at an average price of $29.06, for a total transaction of $100,576.66.
• On Wednesday, September 30th, Soleil Boughton sold 3,461 shares of Hims & Hers Health stock. The stock was sold at an average price of $29.17, for a total transaction of $100,957.37.
• On Wednesday, September 16th, Soleil Boughton sold 6,236 shares of Hims & Hers Health stock. The stock was sold at an average price of $27.86, for a total transaction of $173,734.96.
• On Wednesday, September 2nd, Soleil Boughton sold 3,458 shares of Hims & Hers Health stock. The shares were sold at an average price of $28.33, for a total transaction of $97,965.14.
• On Wednesday, August 19th, Soleil Boughton sold 25,111 shares of Hims & Hers Health stock. The shares were sold at an average price of $27.55, for a total transaction of $691,808.05.

Hims & Hers Health Stock Down 7.0%

Shares of HIMS stock opened at $27.59 on Friday. The company’s fifty day simple moving average is $29.04 and its two-hundred day simple moving average is $27.08. Hims & Hers Health, Inc. has a 52 week low of $13.74 and a 52 week high of $48.34. The stock has a market cap of $6.44 billion, a P/E ratio of -43.79 and a beta of 2.44. The company has a quick ratio of 0.87, a current ratio of 0.93 and a debt-to-equity ratio of 4.21.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings data on Monday, August 10th. The company reported ($0.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.32). Hims & Hers Health had a negative net margin of 5.51% and a negative return on equity of 6.51%. The firm had revenue of $753.21 million for the quarter, compared to analysts’ expectations of $698.90 million. During the same quarter in the previous year, the business earned $0.17 EPS. The company’s revenue for the quarter was up 38.2% on a year-over-year basis. Analysts predict that Hims & Hers Health, Inc. will post -0.16 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

HIMS has been the subject of several recent research reports. Zacks Research upgraded Hims & Hers Health from a “strong sell” rating to a “hold” rating in a research report on Monday, July 13th. Barclays dropped their target price on Hims & Hers Health from $39.00 to $35.00 and set an “overweight” rating for the company in a report on Friday, August 21st. Citigroup decreased their price target on Hims & Hers Health from $35.00 to $33.00 and set a “neutral” rating on the stock in a report on Tuesday, August 11th. Morgan Stanley raised their price target on Hims & Hers Health from $21.00 to $28.00 and gave the stock an “equal weight” rating in a research report on Tuesday, August 11th. Finally, Deutsche Bank Aktiengesellschaft lifted their price objective on shares of Hims & Hers Health from $25.00 to $26.00 and gave the stock a “hold” rating in a research note on Tuesday, August 11th. Three equities research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Hims & Hers Health currently has a consensus rating of “Hold” and a consensus target price of $32.43.

Institutional Trading of Hims & Hers Health

Institutional investors and hedge funds have recently made changes to their positions in the company. Bank of America Corp DE increased its position in Hims & Hers Health by 194.4% during the 1st quarter. Bank of America Corp DE now owns 4,357,672 shares of the company’s stock valued at $90,465,000 after buying an additional 2,877,550 shares in the last quarter. State of Michigan Retirement System grew its stake in shares of Hims & Hers Health by 13.7% during the first quarter. State of Michigan Retirement System now owns 2,338,600 shares of the company’s stock worth $48,549,000 after acquiring an additional 280,900 shares during the last quarter. Bank of New York Mellon Corp purchased a new stake in shares of Hims & Hers Health during the second quarter worth about $46,220,000. Principal Financial Group Inc. increased its holdings in shares of Hims & Hers Health by 97.3% during the first quarter. Principal Financial Group Inc. now owns 1,282,266 shares of the company’s stock valued at $26,620,000 after acquiring an additional 632,282 shares in the last quarter. Finally, Bienville Capital Management LLC acquired a new stake in Hims & Hers Health in the 2nd quarter worth approximately $27,242,000. 63.52% of the stock is currently owned by institutional investors.

Key Headlines Impacting Hims & Hers Health

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: U.S. Department of Health and Human Services reportedly used “enforcement discretion” to temporarily allow compounding of six peptides. The policy could improve Hims & Hers’ access to compounded treatments and support growth, although its temporary nature creates continuing uncertainty. Hims & Hers Jumped as HHS Uses Enforcement Discretion to Open Peptide Compounding
• Positive Sentiment: Earlier strength in telehealth stocks following Teladoc’s better-than-expected results provided some support for Hims & Hers and highlighted continued investor interest in digital-health companies. Teladoc Soars as Revenue and Profit Beat Estimates
• Neutral Sentiment: Insider Soleil Boughton sold 3,462 shares for approximately $95,551 under a pre-arranged Rule 10b5-1 trading plan. The transaction reduced the insider’s position by about 1.16% and is therefore a limited signal about management’s outlook. SEC Insider Trading Filing
• Negative Sentiment: Multiple law firms are soliciting investors ahead of the November 2, 2026 deadline to seek lead-plaintiff status in a federal securities class action covering purchases from August 4, 2025, through July 29, 2026. The litigation stems in part from allegations associated with an FTC complaint and could expose Hims & Hers to legal expenses, potential damages, reputational harm and further scrutiny. The repeated notices appear to be the primary near-term catalyst weighing on the stock. HIMS Securities Class Action Deadline Alert

About Hims & Hers Health

Hims & Hers Health, Inc is a direct-to-consumer health and wellness company that provides telehealth services through the Hims and Hers platforms. The company connects consumers with licensed healthcare providers through online consultations and offers access to prescription and over-the-counter products, as well as educational and wellness resources.

Its services address areas including sexual health, hair loss, skincare, mental health, weight management and primary care. Depending on the condition and eligibility requirements, customers may receive personalized treatment plans and have prescribed medications delivered directly to them.